Enzyme by Design

Enzyme by Design (EbD) is a preclinical stage startup based in Chicago, Illinois, with a team of five employees. Founded with the mission of advancing cancer treatment, EbD focuses its efforts on developing novel oncology biologics. These biologics aim to target and eliminate tumor cells with high effectiveness while minimizing side effects and prioritizing patient safety. EbD specializes in designing protein molecules that specifically target various cancers, including pediatric cancers, acute myeloid leukemia, pancreatic cancer, liver cancer, and ovarian cancer. Their approach leverages protein engineering expertise and integrates patient genomic and epigenetic markers into their clinical strategy. This personalized approach ensures that treatment is tailored to patients most likely to benefit from their innovative biologics. EbD differentiates itself through its commitment to developing biologics that not only treat the disease but also improve patient quality of life and outcomes. By focusing on precision medicine and minimizing side effects, EbD strives to provide a more comprehensive and humane approach to cancer treatment. For more information about Enzyme by Design and their groundbreaking work in oncology, visit their website at enzymebydesign.com.